Arthur Voegel
Education
M.A., economics, Columbia University; M.Phil., economics, University of Cambridge; B.B.A., applied economics, HEC Montréal
Summary of Experience
Mr. Voegel specializes in health economics and outcomes research (HEOR). He has designed and conducted real-world descriptive and comparative studies to evaluate the clinical and economic burden of disease, as well as the effectiveness and cost-effectiveness of therapies. Mr. Voegel has worked with a variety of data sources, including health insurance claims, electronic health records, and survey data. Mr. Voegel’s research spans a wide range of conditions, including chronic urticaria, hidradenitis suppurativa, depression, schizophrenia, cancer, and cirrhosis. Findings from his work have been presented at scientific conferences, including meetings of the International Society for Pharmacoeconomics and Outcomes Research, the Academy of Managed Care Pharmacy, Psych Congress, the American College of Allergy, Asthma & Immunology, the Eastern Allergy Conference, the Association of VA Hematology/Oncology, and the Western Society of Allergy, Asthma & Immunology, among others. His studies have been published in peer-reviewed journals such as Annals of Allergy, Asthma & Immunology; Drugs – Real World Outcomes; the Nephrology Nursing Journal Before joining Analysis Group, Mr. Voegel was a lecturer in the department of applied economics at HEC Montréal.
-
Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray
Neurology and Therapy, 2025
2025Clemens K, Zhdanava M, Teeple A, Voegel A, Shah A, Bowrey HE, Tardif-Samson A, Pilon D, Joshi K
-
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA
Drugs - Real World Outcomes, 2025
2025Jha MK, Zhdanava M, Shah A, Voegel A, Tardif-Samson A, Pilon D, Joshi K
-
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States
Journal of Managed Care & Specialty Pharmacy, 2025
2025Clemens K, Zhdanava M, Teeple A, Voegel A, Joshi K, Shah A, Chen C, Pilon D
-
Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria: Real-world evidence
Annals of Allergy, Asthma & Immunology, 2024
2024Riedl MA, Patil D, Rodrigues J, Kuruvilla M, Raftery T, Pivneva I, Doran J, Voegel A, Signorovitch J, Yosipovitch G
-
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Drugs - Real World Outcomes, 2024
2024Harding L, Joshi K, Zhdanava M, Shah A, Voegel A, Chen C, Pilon D
-
Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional Study
Nephrology Nursing Journal, 2021
2021Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, Guérin A, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T